Scientists create therapy programme to treat depression in women in developing countries
For patients with low back pain caused by a herniated disk, expectations of good results without surgery are the main factor affecting the preference for nonsurgical treatment, reports a study in the November 15 issue of Spine. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider
Full Post: Expectations drive patient preferences for treatment of spine problems
Scientists at the University of Liverpool have developed a therapy programme to treat depression in women in developing countries.
Although depression is a major health problem world-wide, experts say its impact is greatest in developing countries where 80% of the population live. Often there are no resources available to treat sufferers.
Professor Atif Rahman from the School of Population, Community and Behavioural Sciences developed a therapy programme while working as a Wellcome Trust Career Fellow in Tropical Medicine in Rawalpindi, Pakistan.
“Depression is one of the leading causes of mental illness in the world and when the condition affects mothers with newborn babies, it can lead to serious consequences” he says. “The impacts include low birth-weight, poor growth, frequent diarrhoea and the mother failing to ensure the child is properly immunised. These conditions tend to remain untreated in countries like Pakistan where only a fraction of the Government’s budget is spent on health.
The programme, which is designed to be integrated into the routine work of ordinary village-based health workers, has been tested in Rawalpindi. Community health workers visiting expectant mothers are trained to use principles of cognitive behaviour therapy as treatment. Patients attend sessions every week in the last month of pregnancy, followed by three sessions in the first post-natal month, and nine monthly sessions thereafter.
The largest trial of the treatment of depression using community health workers from any country in the developing world involved 903 mothers - 463 of whom were in the therapy group. The mothers from this control group were twice as likely to be depressed as those given the therapy after six and 12 months.
Scientists at the University of Liverpool have developed a therapy programme to treat depression in women in developing countries. Although depression is a major health problem world-wide, experts say its impact is greatest in developing countries where 80% of the population live. Often there are no resources available to treat sufferers. Professor Atif Rahman
Full Post: Study improves recovery for mothers with depression
Health visitors can be trained to identify women with postnatal depression and offer effective treatment, while telephone peer support (mother to mother) may halve the risk of developing postnatal depression, suggests research published on bmj.com. About 13% of women experience postnatal depression in the year following the birth of their child. But postnatal depression is
Full Post: Postnatal depression can be effectively treated and possibly prevented
A new universal test to predict the risk of someone succumbing to major depression has been developed by UCL (University College London) researchers. The online tool, predictD, could eventually be used by family doctors and local clinics to identify those at risk of depression for whom prevention might be most useful. The risk algorithm,
Full Post: New online tool to predict major depression
Researchers at the University of Kentucky found that patients who had negative thinking patterns, such as thoughts about not being able to justify their own existence, were at higher risk for developing depression. Heart patients with depression have been shown to have more complications, including a higher risk of death. Rebecca Dekker, a research nurse,
Full Post: Negative thinking may play a bigger role in heart failure than previously thought
The first melatonergic antidepressant - Valdoxan/Thymanax (agomelatine) - has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for its use in the treatment of adult patients with major depressive disorder (MDD). Upon approval by the European Commission in early 2009, Valdoxan is expected to be
Full Post: Valdoxan - a melatonergic antidepressant - receives positive European opinion for major depressive disorder